Hans Shuhaiber, MD
Neurology · Gainesville, FLNPI 1144412651
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,067 of the $14,503 with a category attached, or 90.1%. AstraZeneca accounts for 84.1% of it on its own, with 1 other manufacturer making up the rest.
Across 15 payments — averaging $966.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$12K
- Jazz Pharmaceuticals Inc.$2K
Across 37 payments — averaging $11,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$268K
- Springworks Therapeutics, Inc.$107K
- Merck$22K
- Jazz Pharmaceuticals Inc.$18K
What the payments were for
- Consulting fees$13,06790%
- Travel & lodging$1,1428%
- Food & beverage$2942%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $12,203 |
| Jazz Pharmaceuticals Inc. | 2 | $2,300 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,503 in reported general payments places this provider in the 80th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 30 | $367,841 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $58,080 |
| Aimovig AutoinjectorErenumab-Aooe | 30 | $22,638 |
| Emgality PenGalcanezumab-Gnlm | 29 | $21,009 |
| QuliptaAtogepant | 13 | $17,415 |
| Gabapentin | 92 | $2,042 |
| Pyridostigmine Bromide | 23 | $1,432 |
| Baclofen | 23 | $1,415 |
| RizatriptanRizatriptan Benzoate | 44 | $1,280 |
| Topiramate | 94 | $1,156 |
| Pregabalin | 16 | $883 |
| Cyclobenzaprine Hcl | 45 | $775 |
| Primidone | 13 | $659 |
| Levetiracetam | 13 | $338 |
| Duloxetine Hcl | 14 | $324 |
Paid to pharmacies, not to this prescriber.
Other neurology in Gainesville
- Adolfo Ramirez ZamoraGainesville$363K
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.